News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
BofAS Raises AKESO (09926.HK) TP to HKD164, Reiterates Buy Rating
BofAS issued a report stating that AKESO (09926.HK) presented the overall survival analysis of the HARMONi-6 study at the oral Plenary Session of ASCO 2026. This marks the first ti...
Reset
Send
The window will close in 5 seconds
BofAS Raises AKESO (09926.HK) TP to HKD164, Reiterates Buy Rating
Close
Recommend
17
Positive
18
Negative
10
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

BofAS issued a report stating that AKESO (09926.HK)  -5.850 (-5.882%)    Short selling $315.46M; Ratio 16.768%   presented the overall survival analysis of the HARMONi-6 study at the oral Plenary Session of ASCO 2026. This marks the first time in ASCOs 61-year history that an innovative oncology drug originally developed in China has been selected for the Plenary Session.

Given the strong HARMONi-6 data, the broker raised the probability of success for the China 1L sqNSCLC indication from 90% to 95%, and increased the probability of success for the global market from 60% to 65%. It also lifted its assumption for ivonescimabs potential market share in China.

Related News CMSI: Three Reasons for Recent Underperformance of Pharma Sector vs HSI; Top Picks INNOVENT BIO (01801.HK), HANSOH PHARMA (03692.HK) and KEYMED BIO-B (02162.HK)
After incorporating these adjustments, the broker increased its revenue forecasts for AKESO for 2026-2028 by 1.7%/1.5%/1.1%, and raised its net profit forecasts by 10.9%/2.8%/3.6%, respectively. The TP was lifted from HKD162.8 to HKD164, with the Buy rating reiterated. The positive view is supported by robust clinical data and multiple upcoming pipeline catalysts. (ha/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-05 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.